Managing MS Treatment During Family Planning
Published on Sat, 20 Jun 2020

Disease-Modifying Drugs and Family Planning in People with Multiple Sclerosis: A Consensus Narrative Review from the Gulf Region
Managing multiple sclerosis (MS) during pregnancy poses challenges due to the risks of disease-modifying drugs (DMDs). Gulf-based experts recommend continuing safer treatments like interferon β, glatiramer acetate, and, in specific cases, natalizumab until 30 weeks of gestation. Immune reconstitution therapies, like cladribine and alemtuzumab, require planning due to prolonged washout periods. Interferon β is also deemed safe for breastfeeding. Experts highlight the need for individualized approaches to balance disease activity management and family planning while addressing data gaps for certain DMDs during breastfeeding.